Reagents
荧光二抗套装 (Alexa Fluor)
- Composition
- Alexa Fluor 488/555/647 等荧光标记二抗(抗兔/抗鼠/抗鸡 IgG),用于 IF 与 mIHC。
- Use information
- 科研实验;规格与库存请向店铺确认。
Published protocol versions
- 脑切片酪氨酸羟化酶(TH)免疫荧光染色 · 二抗孵育 · 抗鸡IgG荧光二抗 1:1000,室温1小时,避光 · 荧光偶联抗鸡IgG二抗;避光保护荧光
Source version:protocols.io · vv1 · Marta Graziano; Ioannis Mantas; Konstantinos Meletis · This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
LRRK2 G2019S transgenic mouse · Verified applicability · 帕金森病 (PD)(LRRK2 G2019S 转基因小鼠用于研究 LRRK2 过表达驱动的神经炎症、运动与情感表型及环境毒素交互。;Verified applicability)6-OHDA-lesioned Wistar rat · Verified applicability · 帕金森病 (PD)(双侧 6-OHDA 损伤 Wistar 大鼠用于研究非运动症状、疼痛、情感障碍及 DBS/神经保护。;Verified applicability)LPS-induced hemiparkinsonian rat · Verified applicability · 帕金森病 (PD)(单侧纹状体 LPS 注射大鼠用于研究微胶质激活、神经炎症驱动的多巴胺能神经元变性和抗炎保护。;Verified applicability)Paraquat plus maneb-treated mouse · Verified applicability · 帕金森病 (PD)(百草枯联合代森锰暴露小鼠用于研究环境农药相关的多巴胺能易感性和基因—环境交互。;Verified applicability)PINK1 knockout mouse · Verified applicability · 帕金森病 (PD)(PINK1 敲除小鼠用于研究线粒体质量控制与遗传性帕金森病机制;多数品系基线无明显黑质纹状体退变。;Verified applicability)Rotenone-treated Wistar rat · Verified applicability · 帕金森病 (PD)(鱼藤酮处理 Wistar 大鼠用于研究线粒体复合体 I 功能障碍、α-突触核蛋白病理和神经保护。;Verified applicability)6-OHDA-lesioned Sprague-Dawley rat · Verified applicability · 帕金森病 (PD)(6-OHDA 损伤 Sprague-Dawley 大鼠用于研究黑质纹状体变性机制、神经保护、DBS 和运动/非运动表型。;Verified applicability)LRRK2 G2019S knock-in mouse · Verified applicability · 帕金森病 (PD)(LRRK2 G2019S 敲入小鼠用于研究内源表达水平下 LRRK2 对多巴胺轴突释放和突触功能的调节。;Verified applicability)Reserpine-treated mouse · Verified applicability · 帕金森病 (PD)(利血平处理小鼠用于研究 VMAT2 介导的单胺耗竭、可逆性帕金森样运动障碍和药物反应。;Verified applicability)6-OHDA-lesioned C57BL/6 mouse · Verified applicability · 帕金森病 (PD)(单侧纹状体 6-OHDA 损伤 C57BL/6 小鼠用于研究遗传修饰、神经炎症和运动不对称。;Verified applicability)MPTP-treated Swiss mouse · Verified applicability · 帕金森病 (PD)(MPTP 处理 Swiss 小鼠用于研究品系依赖的黑质生化和结构改变;其多巴胺能神经元丢失通常弱于 C57BL/6。;Verified applicability)alpha-synuclein PFF-injected C57BL/6J mouse · Verified applicability · 帕金森病 (PD)(纹状体注射 α-突触核蛋白预制纤维用于研究模板化聚集、病理传播、免疫清除及多巴胺能易感性。;Verified applicability)A30P alpha-synuclein transgenic mouse (Thy1 promoter) · Verified applicability · 帕金森病 (PD)(Thy1-A30P α-突触核蛋白转基因小鼠用于研究年龄依赖性精细运动障碍、α-突触核蛋白聚集和突触功能异常。;Verified applicability)Rotenone-treated mouse · Verified applicability · 帕金森病 (PD)(鱼藤酮暴露小鼠用于研究线粒体复合体 I 抑制、α-突触核蛋白蓄积及黑质纹状体多巴胺能变性。;Verified applicability)DJ-1 knockout mouse · Verified applicability · 帕金森病 (PD)(DJ-1 敲除小鼠用于研究 DJ-1 抗氧化功能及对 MPTP/氧化应激的易感性;基线表型较轻。;Verified applicability)Parkin knockout mouse · Verified applicability · 帕金森病 (PD)(Parkin 敲除小鼠用于研究 Parkin 在丝裂自噬和 dopamine 神经元维持中的作用;基线神经退变较轻,适用于机制与应激易感性研究。;Verified applicability)6-OHDA 损伤帕金森样模型(大鼠,文献参考) · Verified applicability · 帕金森病 (PD)(6-OHDA 损伤范式下多巴胺能进行性退变研究的文献参考模型;适用性限于该损伤模型范围;Verified applicability)C57BL/6 MPTP 黑质纹状体变性参考模型(文献参考) · Verified applicability · 帕金森病 (PD)(MPTP 诱导黑质纹状体多巴胺能变性研究的文献参考模型;适用性限于化学诱导范式下的神经退行性表型与近交品系间反应比较;Verified applicability)MitoPark mouse · Verified applicability · 帕金森病 (PD)(MitoPark 小鼠用于研究线粒体 DNA 维持、年龄依赖性黑质纹状体退变、运动与情感表型及线粒体靶向干预。;Verified applicability)MPTP-treated mouse (strain not specified) · Verified applicability · 帕金森病 (PD)(MPTP诱导小鼠用于帕金森病相关运动功能和黑质纹状体损伤研究;本记录不指定原文未报告的品系。;Verified applicability)A53T alpha-synuclein transgenic mouse · Verified applicability · 帕金森病 (PD)(A53T α-突触核蛋白表达(转基因或 AAV 递送)用于研究聚集、传播、突触功能障碍和运动表型;不同启动子/载体分别解释,M83 另列。;Verified applicability)6-OHDA-lesioned mouse · Verified applicability · 帕金森病 (PD)(6-OHDA损伤小鼠用于研究黑质纹状体损伤及神经保护;本条来源未限定品系,不代表某一特定近交系。;Verified applicability)AAV-human alpha-synuclein overexpression mouse · Verified applicability · 帕金森病 (PD)(AAV 介导的人 α-突触核蛋白过表达用于研究黑质多巴胺能病理、传播和神经保护。;Verified applicability)BAC human SNCA transgenic rat · Verified applicability · 帕金森病 (PD)(BAC 人 SNCA 转基因大鼠用于研究人 α-突触核蛋白表达及年龄依赖性病理。;Verified applicability)LRRK2 R1441G BAC transgenic mouse · Verified applicability · 帕金森病 (PD)(LRRK2 R1441G BAC 转基因小鼠用于研究 LRRK2 过表达对多巴胺传递和运动表型的影响。;Verified applicability)Snca G51D knock-in mouse · Verified applicability · 帕金森病 (PD)(Snca G51D 敲入小鼠用于研究 G51D α-突触核蛋白病理、纤毛和突触改变。;Verified applicability)TCE-treated Lewis rat · Verified applicability · 帕金森病 (PD)(三氯乙烯暴露 Lewis 大鼠用于研究环境毒素相关的多巴胺能毒性。;Verified applicability)Rotenone-treated rat · Verified applicability · 帕金森病 (PD)(鱼藤酮暴露大鼠用于研究帕金森病相关线粒体功能障碍及多巴胺能损伤;全身毒性、死亡率及表型变异限制其适用性。;Verified applicability)Paraquat-treated mouse · Verified applicability · 帕金森病 (PD)(百草枯暴露小鼠用于研究帕金森病相关氧化应激和多巴胺能毒性;不能等同于完整复现人类疾病。;Verified applicability)Paraquat-treated rat · Verified applicability · 帕金森病 (PD)(百草枯暴露Sprague-Dawley大鼠用于研究帕金森病相关抗氧化防御受损及中脑GPx变化;该依据不证明完整运动表型或稳定黑质退变。;Verified applicability)AAV-human alpha-synuclein overexpression rat · Verified applicability · 帕金森病 (PD)(人α-突触核蛋白过表达大鼠用于研究运动不对称及TH阳性神经元损伤。;Verified applicability)E46K alpha-synuclein BAC transgenic rat · Verified applicability · 帕金森病 (PD)(E46K BAC转基因大鼠用于研究α-突触核蛋白聚集及毒素易感性;文献未见12月龄明确多巴胺能神经元丢失或明显运动缺陷。;Verified applicability)LRRK2 R1441C knock-in mouse · Verified applicability · 帕金森病 (PD)(LRRK2 R1441C敲入小鼠用于研究多巴胺传递和D2受体功能;不代表已出现自发多巴胺能退变或α-突触核蛋白积累。;Verified applicability)PINK1 knockout rat · Verified applicability · 帕金森病 (PD)(PINK1敲除大鼠用于研究年龄相关多巴胺能损伤、运动功能及α-突触核蛋白病理,表型具有研究条件依赖性。;Verified applicability)Parkin knockout rat · Verified applicability · 帕金森病 (PD)(Parkin敲除大鼠用于研究帕金森病相关蛋白稳态及蛋白组机制;文献未显示明确行为缺陷或多巴胺能神经元丢失。;Verified applicability)DJ-1 knockout rat · Verified applicability · 帕金森病 (PD)(DJ-1敲除大鼠用于研究帕金森病相关多巴胺能退变和运动功能,表型随年龄及研究条件变化。;Verified applicability)alpha-synuclein PFF-injected rat · Verified applicability · 帕金森病 (PD)(α-突触核蛋白PFF大鼠用于研究病理传播和黑质多巴胺能损伤;所引研究未见明显运动缺陷。;Verified applicability) - 脑切片酪氨酸羟化酶(TH)免疫荧光染色 · 二抗孵育 · 抗鸡IgG荧光二抗 1:1000,室温1小时,避光 · 荧光偶联抗鸡IgG二抗;避光保护荧光
Source version:protocols.io · vv1 · Marta Graziano; Ioannis Mantas; Konstantinos Meletis · This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
alpha-synuclein PFF-injected rat · Verified applicability · 帕金森病 (PD)(α-突触核蛋白PFF大鼠用于研究病理传播和黑质多巴胺能损伤;所引研究未见明显运动缺陷。;Verified applicability)DJ-1 knockout rat · Verified applicability · 帕金森病 (PD)(DJ-1敲除大鼠用于研究帕金森病相关多巴胺能退变和运动功能,表型随年龄及研究条件变化。;Verified applicability)Parkin knockout rat · Verified applicability · 帕金森病 (PD)(Parkin敲除大鼠用于研究帕金森病相关蛋白稳态及蛋白组机制;文献未显示明确行为缺陷或多巴胺能神经元丢失。;Verified applicability)PINK1 knockout rat · Verified applicability · 帕金森病 (PD)(PINK1敲除大鼠用于研究年龄相关多巴胺能损伤、运动功能及α-突触核蛋白病理,表型具有研究条件依赖性。;Verified applicability)LRRK2 R1441C knock-in mouse · Verified applicability · 帕金森病 (PD)(LRRK2 R1441C敲入小鼠用于研究多巴胺传递和D2受体功能;不代表已出现自发多巴胺能退变或α-突触核蛋白积累。;Verified applicability)E46K alpha-synuclein BAC transgenic rat · Verified applicability · 帕金森病 (PD)(E46K BAC转基因大鼠用于研究α-突触核蛋白聚集及毒素易感性;文献未见12月龄明确多巴胺能神经元丢失或明显运动缺陷。;Verified applicability)AAV-human alpha-synuclein overexpression rat · Verified applicability · 帕金森病 (PD)(人α-突触核蛋白过表达大鼠用于研究运动不对称及TH阳性神经元损伤。;Verified applicability)Paraquat-treated rat · Verified applicability · 帕金森病 (PD)(百草枯暴露Sprague-Dawley大鼠用于研究帕金森病相关抗氧化防御受损及中脑GPx变化;该依据不证明完整运动表型或稳定黑质退变。;Verified applicability)Paraquat-treated mouse · Verified applicability · 帕金森病 (PD)(百草枯暴露小鼠用于研究帕金森病相关氧化应激和多巴胺能毒性;不能等同于完整复现人类疾病。;Verified applicability)Rotenone-treated rat · Verified applicability · 帕金森病 (PD)(鱼藤酮暴露大鼠用于研究帕金森病相关线粒体功能障碍及多巴胺能损伤;全身毒性、死亡率及表型变异限制其适用性。;Verified applicability)TCE-treated Lewis rat · Verified applicability · 帕金森病 (PD)(三氯乙烯暴露 Lewis 大鼠用于研究环境毒素相关的多巴胺能毒性。;Verified applicability)Snca G51D knock-in mouse · Verified applicability · 帕金森病 (PD)(Snca G51D 敲入小鼠用于研究 G51D α-突触核蛋白病理、纤毛和突触改变。;Verified applicability)LRRK2 R1441G BAC transgenic mouse · Verified applicability · 帕金森病 (PD)(LRRK2 R1441G BAC 转基因小鼠用于研究 LRRK2 过表达对多巴胺传递和运动表型的影响。;Verified applicability)BAC human SNCA transgenic rat · Verified applicability · 帕金森病 (PD)(BAC 人 SNCA 转基因大鼠用于研究人 α-突触核蛋白表达及年龄依赖性病理。;Verified applicability)AAV-human alpha-synuclein overexpression mouse · Verified applicability · 帕金森病 (PD)(AAV 介导的人 α-突触核蛋白过表达用于研究黑质多巴胺能病理、传播和神经保护。;Verified applicability)6-OHDA-lesioned mouse · Verified applicability · 帕金森病 (PD)(6-OHDA损伤小鼠用于研究黑质纹状体损伤及神经保护;本条来源未限定品系,不代表某一特定近交系。;Verified applicability)A53T alpha-synuclein transgenic mouse · Verified applicability · 帕金森病 (PD)(A53T α-突触核蛋白表达(转基因或 AAV 递送)用于研究聚集、传播、突触功能障碍和运动表型;不同启动子/载体分别解释,M83 另列。;Verified applicability)MPTP-treated mouse (strain not specified) · Verified applicability · 帕金森病 (PD)(MPTP诱导小鼠用于帕金森病相关运动功能和黑质纹状体损伤研究;本记录不指定原文未报告的品系。;Verified applicability)MitoPark mouse · Verified applicability · 帕金森病 (PD)(MitoPark 小鼠用于研究线粒体 DNA 维持、年龄依赖性黑质纹状体退变、运动与情感表型及线粒体靶向干预。;Verified applicability)C57BL/6 MPTP 黑质纹状体变性参考模型(文献参考) · Verified applicability · 帕金森病 (PD)(MPTP 诱导黑质纹状体多巴胺能变性研究的文献参考模型;适用性限于化学诱导范式下的神经退行性表型与近交品系间反应比较;Verified applicability)6-OHDA 损伤帕金森样模型(大鼠,文献参考) · Verified applicability · 帕金森病 (PD)(6-OHDA 损伤范式下多巴胺能进行性退变研究的文献参考模型;适用性限于该损伤模型范围;Verified applicability)Parkin knockout mouse · Verified applicability · 帕金森病 (PD)(Parkin 敲除小鼠用于研究 Parkin 在丝裂自噬和 dopamine 神经元维持中的作用;基线神经退变较轻,适用于机制与应激易感性研究。;Verified applicability)DJ-1 knockout mouse · Verified applicability · 帕金森病 (PD)(DJ-1 敲除小鼠用于研究 DJ-1 抗氧化功能及对 MPTP/氧化应激的易感性;基线表型较轻。;Verified applicability)Rotenone-treated mouse · Verified applicability · 帕金森病 (PD)(鱼藤酮暴露小鼠用于研究线粒体复合体 I 抑制、α-突触核蛋白蓄积及黑质纹状体多巴胺能变性。;Verified applicability)A30P alpha-synuclein transgenic mouse (Thy1 promoter) · Verified applicability · 帕金森病 (PD)(Thy1-A30P α-突触核蛋白转基因小鼠用于研究年龄依赖性精细运动障碍、α-突触核蛋白聚集和突触功能异常。;Verified applicability)alpha-synuclein PFF-injected C57BL/6J mouse · Verified applicability · 帕金森病 (PD)(纹状体注射 α-突触核蛋白预制纤维用于研究模板化聚集、病理传播、免疫清除及多巴胺能易感性。;Verified applicability)MPTP-treated Swiss mouse · Verified applicability · 帕金森病 (PD)(MPTP 处理 Swiss 小鼠用于研究品系依赖的黑质生化和结构改变;其多巴胺能神经元丢失通常弱于 C57BL/6。;Verified applicability)6-OHDA-lesioned C57BL/6 mouse · Verified applicability · 帕金森病 (PD)(单侧纹状体 6-OHDA 损伤 C57BL/6 小鼠用于研究遗传修饰、神经炎症和运动不对称。;Verified applicability)Reserpine-treated mouse · Verified applicability · 帕金森病 (PD)(利血平处理小鼠用于研究 VMAT2 介导的单胺耗竭、可逆性帕金森样运动障碍和药物反应。;Verified applicability)LRRK2 G2019S knock-in mouse · Verified applicability · 帕金森病 (PD)(LRRK2 G2019S 敲入小鼠用于研究内源表达水平下 LRRK2 对多巴胺轴突释放和突触功能的调节。;Verified applicability)6-OHDA-lesioned Sprague-Dawley rat · Verified applicability · 帕金森病 (PD)(6-OHDA 损伤 Sprague-Dawley 大鼠用于研究黑质纹状体变性机制、神经保护、DBS 和运动/非运动表型。;Verified applicability)Rotenone-treated Wistar rat · Verified applicability · 帕金森病 (PD)(鱼藤酮处理 Wistar 大鼠用于研究线粒体复合体 I 功能障碍、α-突触核蛋白病理和神经保护。;Verified applicability)PINK1 knockout mouse · Verified applicability · 帕金森病 (PD)(PINK1 敲除小鼠用于研究线粒体质量控制与遗传性帕金森病机制;多数品系基线无明显黑质纹状体退变。;Verified applicability)Paraquat plus maneb-treated mouse · Verified applicability · 帕金森病 (PD)(百草枯联合代森锰暴露小鼠用于研究环境农药相关的多巴胺能易感性和基因—环境交互。;Verified applicability)LPS-induced hemiparkinsonian rat · Verified applicability · 帕金森病 (PD)(单侧纹状体 LPS 注射大鼠用于研究微胶质激活、神经炎症驱动的多巴胺能神经元变性和抗炎保护。;Verified applicability)6-OHDA-lesioned Wistar rat · Verified applicability · 帕金森病 (PD)(双侧 6-OHDA 损伤 Wistar 大鼠用于研究非运动症状、疼痛、情感障碍及 DBS/神经保护。;Verified applicability)LRRK2 G2019S transgenic mouse · Verified applicability · 帕金森病 (PD)(LRRK2 G2019S 转基因小鼠用于研究 LRRK2 过表达驱动的神经炎症、运动与情感表型及环境毒素交互。;Verified applicability)MPTP-lesioned non-human primate · Verified applicability · 帕金森病 (PD)(MPTP 损伤非人灵长类用于研究帕金森样运动障碍、左旋多巴诱导的运动障碍及多巴胺替代治疗。;Verified applicability)